Safety, pharmacokinetics, pharmacogenomics and QT concentration−effect modelling of the SirT1 inhibitor selisistat in healthy volunteers-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, pharmacogenomics and QT concentration−effect modelling of the SirT1 inhibitor selisistat in healthy volunteers

Author:

Westerberg Goran¹²,Chiesa Joseph A.³,Andersen Claus A.¹,Diamanti Daniela¹,Magnoni Letizia¹,Pollio Giuseppe¹,Darpo Borje⁴⁵,Zhou Meijian⁵

Affiliation:

1. Siena Biotech SpA; 35, Strada del Petriccio e Belriguardo 53100 Siena Italy

2. La Crocina Pharmaceutical Consultants D.I.; Podere La Crocina 53020 San Giovanni d'Asso Italy

3. Covance Clinical Research Ltd; Springfield House Leeds LS2 9LH West Yorkshire United Kingdom

4. Department of Clinical Sciences; Division of Cardiovascular Medicine; Karolinska Institute; Danderyd's Hospital; Stockholm Sweden

5. iCardiac Technologies, Inc.; 150 Allens Creek Road Rochester NY 14618 USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference22 articles.

2. Huntington's disease;Walker;Lancet,2007

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献